© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
American Headache Society Annual Scientific Meeting
Potential Layered Migraine Treatment Approaches to Research: Andrew Blumenfeld, MD
June 17, 2021
The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.
Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs
June 12, 2021
Neurology News Network for the week ending June 12, 2021.
Investigating INP104 for Migraine Treatment: Carrie Dougherty, MD, FAHS
June 10, 2021
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.
Clinically Meaningful Improvements in Migraine Achievable With Synchronous Telemedicine
June 10, 2021
The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.
Concomitant Use of Ubrogepant With CGRP Monoclonal Antibodies: Richard B. Lipton, MD
June 10, 2021
The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.
Rimegepant Achieves Migraine Prevention After 1 Week of Treatment
June 09, 2021
A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.
Nasal Delivery of DHE for Migraine: Carrie Dougherty, MD, FAHS
June 09, 2021
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the advantages of INP104 over other forms of dihydroergotamine.
New Migraine Burden Index Proves Accurate, Strongly Correlates With Patient Satisfaction
June 09, 2021
Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.
Despite Slight Differences, Preventive Migraine Therapies Demonstrate High Efficacy
June 09, 2021
Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.
NeuroVoices: Andrew Blumenfeld, MD, on a Combination Approach to Treating Chronic Migraine
June 09, 2021
The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.